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Purpose
The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacody-
namic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with
liver metastasis (CRCLM).
Materials and Methods
From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received
bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the
patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktrans and IAUC60) was performed
at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up
(3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], pla-
cental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progres-
sion-free survival (PFS) time distributions were summarized using the Kaplan-Meier method
and compared using log-rank tests.
Results
The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first
follow-up day were significantly different compared with baseline values. No differences
were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first
follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval,
0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. 
Conclusion
DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for
CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a 
favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not
found.
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Introduction
The combination of bevacizumab with cytotoxic chem-
otherapy has been proved to have survival benefits in 
patients with metastatic colorectal cancer [1-3]. This combi-
nation has been approved by the US Food and Drug Admin-
istration (Washington, DC) as a first-line treatment [2].
Bevacizumab is an inhibitor of vascular endothelial growth
factor (VEGF). It normalizes the abnormal vascular struc-
tures in tumor stroma, decreases the elevated interstitial
pressure in tumors, and alleviates the hypoxic tumor 
microenvironment [4]. In addition to the direct antiangio-
genic effects, these changes also increase chemotherapeutic
efficacy. The standard protocol uses combination therapy
with cytotoxic agents but does not include bevacizumab
mono-therapy [2]. One major issue for the combination ther-
apy is that clinicians cannot distinguish the effects of beva-
cizumab alone from the effects of the cytotoxic agents used
in the protocol. Despite the benefit of bevacizumab on clini-
cal outcome, a substantial number of patients do not respond
to the therapy targeting VEGF, or they develop resistance to
the drug over time. There is also an increased chance of seri-
ous side effects (e.g., stroke and gastrointestinal perforation)
in patients treated with VEGF-targeted therapy [2,5]. In 
addition, the target agents are expensive. There is a critical
need for identification of reliable biomarkers for prediction
of tumor response to treatment and to predict which patients
are likely to benefit from bevacizumab. 
Plasma cytokines and angiogenic factors (CAFs) are poten-
tial biomarkers that reflect the systemic condition of patients
with colorectal cancer treated with bevacizumab combined
with cytotoxic chemotherapy [6]. Elevated baseline inter-
leukin 8 (IL-8) is associated with a shorter progression-free
survival (PFS) time. Levels of some plasma CAFs associated
with angiogenesis and myeloid recruitment increase com-
pared to baseline, before radiographic progression [7].
Plasma CAFs could be potential biomarkers of response and
resistance to bevacizumab, but they cannot reflect the local
response of the tumor microenvironment and cannot differ-
entiate the response of the tumor from that of the host tissue
[7].
Unlike plasma CAFs used as systemic biomarkers, an 
imaging biomarker can reflect local tumor condition. How-
ever, tumor size may not be a reliable marker for assessment
of the early effects of antiangiogenic agents because many of
these new drugs act directly on endothelial cells, not on the
tumor cells. Therefore, the effects of the agents are expected
to be primarily cytostatic rather than cytotoxic [8]. As an 
alternative functional modality, dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) is a noninvasive
and appropriate method for evaluating the efficacy of these
antiangiogenic therapies using changes in tumor vascular
perfusion, vascular permeability, and interstitial and intra-
vascular volumes, without exposure to ionizing radiation [8].
The volume transfer constant (Ktrans) and the initial area
under the gadolinium concentration-time curve (IAUC) have
been proposed as useful parameters that reflect the vascular
response [8]. These parameters can be used with DCE-MRI
to quantify the effects of antiangiogenic therapy during the
early response period.
Several studies have reported reduction in Ktrans within a
few days of bevacizumab treatment [8,9]. Some studies of 
bevacizumab in colorectal cancer suggest that DCE-MRI may
be related to clinical outcome [10,11]. In addition, several
studies of anti-VEGF tyrosine kinase inhibitors have shown
that reduction in Ktrans and/or IAUC may distinguish respon-
ders from non-responders [12-14]. Based on those studies,
patients with a smaller change in Ktrans are predicted to have
a shorter PFS time and to receive less clinical benefit from the
treatment. However, when applying the results in the clinical
practice setting, the clinician must determine whether the 
patients should stop receiving only bevacizumab, only the
cytotoxic agent, or both bevacizumab and the cytotoxic
agent. This is because the clinician cannot determine whether
the change in Ktrans results from the effect of the bevacizumab
alone, the cytotoxic agent, or both. 
To gain insight into the mechanisms of action and the pure
effects of bevacizumab, we designed an exploratory trial
with a single-arm of bevacizumab monotherapy followed by
combined therapy. The effects of bevacizumab alone on both
tumor physiology and systemic response were evaluated by
measuring DCE-MRI parameters and plasma CAF levels.
The primary objective of this phase II clinical trial was to 
determine prognostic biomarkers of bevacizumab alone that
might show correlation with clinical outcomes. Our study
also revealed the antiangiogenic effect of bevacizumab
monotherapy on local tumor response using changes in
DCE-MRI, and on systemic response using changes in
plasma CAFs.
Materials and Methods
This study was registered at http://www.clnicaltrials.gov
(NCT01318239). The study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
Guidelines. Protocol approval was obtained from the Insti-
tutional Review Board of Severance Hospital, Yonsei Univer-
sity College of Medicine (Seoul, Korea). Written informed
consent was obtained from each patient. 
1212 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2016;48(4):1210-1221
1. Patient population
Patients aged  20 years with histologically confirmed col-
orectal cancer and one or more measurable hepatic metas-
tases  2 cm diameter were enrolled in the study. 
Patients with standard contraindications for MRI and/or
gadolinium-based contrast agents, pregnant or breast-feed-
ing women, and patients with decreased renal function 
(creatinine > 1.5 mg/dL, blood urea nitrogen > 30 mg/dL),
who had prior chemotherapy, concurrent malignancies or
significant medical comorbidities, and who had received any
treatment as part of a clinical trial were excluded from the
study.
2. Study design
In this single group, exploratory trial, patients were treated
with bevacizumab (5 mg/kg intravenous) alone on day 1,
followed by a concurrent FOLFOX-6+B regimen (beva-
cizumab/oxaliplatin/5-fluorouracil/leucovorin) on day 7.
Reduction in dose of the cytotoxic chemotherapy was 
required for grade 3 or 4 toxicities that were adverse events
of however, the dose of bevacizumab, was not reduced. 
Adverse events were graded using the National Cancer 
Institute Common Terminology Criteria for Adverse Events
ver. 3.0. Treatment was continued until documentation of
unacceptable toxicities, disease progression, or withdrawal
of consent.
DCE-MRI and blood sampling for plasma CAFs were per-
formed on the day before treatment was initiated (baseline),
on day 3 after the patients received bevacizumab monother-
apy (first follow-up), and on day 3 after receiving the com-
bined chemotherapy (second follow-up) (Fig. 1).
The primary endpoint was the correlation between the
changes in DCE-MRI parameters (from baseline to 3 days
after administration of bevacizumab monotherapy) with PFS
time. The standard DCE-MRI parameters (Ktrans and IAUC60)
were measured during each imaging and the changes from
baseline to first follow-up and from first follow-up to second
follow-up were calculated. The baseline values were dicho-
tomized according to the low and high group based on the
median value. The changes in the DCE-MRI parameters were
dichotomized according to larger and smaller change
groups, using a 40% change as the cut-off value. This cut-off
value of 40% was chosen because a 40% reduction in Ktrans is
necessary before a favorable clinical response can be detected
[11-13,15,16]. Dichotomized values of the baseline and the
changes were correlated with PFS. The changes in tumor size
were also measured at baseline, first follow-up, and second
follow-up.
The secondary endpoints included the correlation between
changes in plasma CAFs from baseline to 3 days after beva-
cizumab monotherapy, with PFS and toxicity. For correlation
with clinical outcomes, plasma CAF values were dichoto-
mized by calculating optimal cut-off values, obtained from
receiver operating characteristic curve analysis. 
PFS was defined as the period from the enrollment date
until the documented tumor progression date. Data were
censored for the patients who were alive without disease
progression at the last follow-up date. Computed tomogra-
phy (CT) examination with contrast enhancement was per-
formed before and every 3 months after treatment. Tumor
response evaluated at 3 months after the treatment was 
dichotomized according to a partial response group and a
stable disease or disease progression group. Assessment of
tumor response was performed in accordance with the 
Response Evaluation Criteria in Solid Tumors (RECIST) ver.
1.1 guidelines [17]. 
3. DCE-MRI study
For reproducibility, consistent DCE-MRI methods were
followed using a 3-T MR scanner (MAGNETOM Tim Trio,
Siemens Healthcare, Erlangen, Germany) equipped with 
8-channel body phased-array coils (Siemens Healthcare).
Each patient fasted for at least 4 hours before the scan was
performed. 
T1 mapping was obtained before acquisition of perfusion
images to convert signal intensities of perfusion images into
gadolinium concentration values. T1 maps were calculated
from two flip angle scans using 2° and 14°:
S(, T1, TR)= S0
Sin(1–exp(–TR/T1))   
, T1(t)=T10+r1*c(t),
1–cos() exp(–TR/T1)
where T1(t): T1 dynamic; T10: T1 before contrast; r1: T1 relax-
ivity of the contrast agent; and c(t): contrast agent concentra-
tion.
Axial images for the T1 maps were obtained using three-
dimensional (3D) spoiled gradient echo sequences with two
different flip angles (2° and 14°) and a fixed repetition
time/echo time (TR/TE; 4.91 msec /1.71 msec). A total of 
20 slices per sequence using a different flip angle were 
acquired. The slice thickness was 3.6 mm and the in-plane
resolution was 1.671.67 mm2 for each in one breath-hold
and scan time of 18 seconds.
Perfusion images were obtained using 3D T1-weighted
time resolved angiography with stochastic trajectories
(TWIST) sequence (TR/TE, 4.51 msec/1.76 msec; slice thick-
ness, 3.6 mm; flip angle, 12°; matrix size, 192138; field of
view, 300 mm; band width, 250 Hz/Px). Serial images (tem-
poral resolution, 0.295 seconds) were acquired during shal-
low, free-breathing respiration. Twenty axial image slices
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(range, 10 cm) per cycle were obtained while centered on the
center of the tumor (5.9 seconds for one cycle). Perfusion 
images were acquired repetitively over 75 cycles for 7-8 min-
utes. A total volume of 15 mL Omniscan (gadodiamide, GE
Healthcare, Oslo, Norway) was used as a contrast material,
and was injected intravenously using an automatic injector
at a rate of 5 mL/sec, followed by a 30-mL saline injection.
An algorithm with a diffeomorphism flow was introduced
for registration between the T1 mapping sequence and the
perfusion imaging sequence. The algorithm was based on
maximization of statistical similarity criteria (local and
global) in a variational framework. This flow was adjusted
using a template propagation method by composition of
small displacements. Regularization was achieved using fast
filtering techniques. This approach combined the robustness
of statistical similarity measures with the flexibility of diffeo-
morphic matching techniques [18]. 
A commercial post-processing software based on a modi-
fied Tofts model (Tissue 4D, Siemens Medical Solutions) and
installed at an image processing workstation (Leonardo,
Siemens Medical Solutions), was used for calculation of the
quantitative perfusion parameters. Motion correction was
performed using the non-rigid body algorithm on the post-
processing software. For analysis of the perfusion data, the
arterial input function was set as the average bi-exponential
function using fast mode. Color-coded maps of the Ktrans val-
ues were acquired through data processing. IAUC60 values
for the first 60s from the contrast injection were also acquired.
Two dimensional regions of interest (ROIs) were hand-
drawn on post-processed images by an abdominal radiolo-
gist with 7 years experience, according to the tumor margin
through the midline of the z-axis of the tumor in the section
where the largest transverse diameter of liver metastasis was
detected. ROIs were drawn for all tumors > 2 cm in diameter
and a mean value for Ktrans was estimated for all patients with
multiple lesions. Unlike RECIST, the commonly used crite-
rion for measurable lesions on DCE-MRI is > 2 cm in diame-
ter, in consideration both of size reduction and measurement
error [10]. 
The baseline Ktrans and IAUC60 values were acquired from
the baseline study results. The values for these same param-
eters were assessed from the first follow-up and second fol-
low-up images. The changes were calculated as absolute and
percentage values.
4. Plasma sample collection and analysis
Blood samples were collected for circulating pharmacody-
namics marker studies prior to the initial bevacizumab infu-
sion, on the third day after bevacizumab monotherapy, and
on the third day after combined therapy. Serum samples
were assayed for circulating VEGF-A, placental growth fac-
tor (PlGF), soluble vascular endothelial growth factor recep-
tor 2 (sVEGFR2), and IL-8 using enzyme-linked immuno-
sorbent assay kits (R&D Systems, Minneapolis, MN). The
changes were calculated as absolute and percentage values.
5. Statistical analysis
DCE-MRI parameter and plasma CAF values were corre-
lated with PFS. Baseline values and the changes in the DCE-
MRI parameters and CAF values were analyzed to determine
correlations among the parameters. 
Kaplan-Meier estimates and log-rank tests were computed
to evaluate the associations between changes in DCE-MRI
parameter or plasma CAF values with the length of PFS or
overall survival (OS). Analyses of associations between base-
line values of DCE-MRI parameters or plasma CAFs with
PFS or OS were also performed.
The PFS and OS times were estimated using the Kaplan-
Day 0: Baseline
    DCE-MRI
    Plasma CAFs
Day 1
    Bevacizumab monotherapy start
Day 7
    FOLFOX-6+B start
Day 4: 1st follow-up
    DCE-MRI
    Plasma CAFs
Day 10: 2nd follow-up
    DCE-MRI
    Plasma CAFs
Fig. 1. Study design. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies and blood sampling for
plasma cytokine and angiogenic factors (CAFs) were performed 1 day before treatment (day 0). Patients were treated with
bevacizumab (5 mg/kg intravenously) alone on day 1 and the first follow-up DCE-MRI and blood sampling for plasma
CAFs were performed 3 days after the monotherapy treatment (day 4). A concurrent FOLFOX-6+B regimen
(bevacizumab/oxaliplatin/5-fluorouracil/leucovorin) was administered on day 7 and the second follow-up DCE-MRI and
blood sampling for plasma CAFs were performed 3 days after combined chemotherapy (day 10).
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Meier method. The differences among the patient groups for
PFS, OS, and treatment response were compared using mul-
tivariate Cox regression analysis. Six parameters were con-
sidered as possible covariates in the regression analysis. The
associations among the categorical variables and the contin-
uous variables were analyzed using chi-square tests and lin-
ear mixed models, respectively.
For all analyses, a p-value < 0.05 was considered statisti-
cally significant. SPSS ver. 18.0 (SPSS Inc., Chicago, IL) and
SAS ver. 9.2 (SAS Institute Inc., Cary, NC) were used for all
analyses.
Results
1. Patient characteristics and clinical outcomes
Thirty-two patients were enrolled in the study between
July 2011 and March 2012. Four patients were excluded from
the analysis due to follow-up loss (n=3) or imaging error
(n=1). The mean age of the patients was 57 years (range, 30
to 77 years), and a total of 60 hepatic metastatic lesions in 
patients with rectal cancer (n=8) and colon cancer (n=20)
were analyzed. The Eastern Cooperative Oncology Group
performance status score was 0 for 22 patients and 1 for 
six patients. The mean baseline carcinoembryonic antigen
value was 340.78 ng/mL. 
The median PFS time was 11.2 months (95% confidence 
interval [CI], 6.9 to 15.5), and the median OS time was 22.7
months (95% CI, 18.8 to 26.7). 
In assessment of tumor response on 3-month follow-up CT
images according to RECIST ver. 1.1, 13 patients showed par-
tial response and 14 patients showed stable disease. Only one
patient showed disease progression on the 3-month follow-
up. Dose reduction was required for five of 28 patients due
to toxicity during the course of the scheduled treatment. 
Fatigue and neuropathy were the most common adverse
events. Neutropenia was the most frequent of the grade 3 or
4 adverse events (Table 1).
2. DCE-MRI parameters and plasma CAFs as pharmacody-
namic biomarkers 
The results for the changes in DCE-MRI parameters,
plasma CAF values, and tumor size at 3 days after beva-
cizumab monotherapy (first follow-up) and at 3 days after
combined chemotherapy (second follow-up) are shown in
Fig. 2. Compared with the baseline values, the Ktrans, IAUC60,
and serum VEGF values at the first follow-up evaluation had
decreased (p < 0.05). No significant changes were detected
at the second follow-up evaluation compared to the first fol-
low-up. Serum PlGF was elevated at the first follow-up eval-
uation and was still elevated at the second follow-up
evaluation. There were no significant changes in sVEGFR2,
IL-8, and size, and no significant correlations were observed
between the changes in DCE-MRI parameters and plasma
CAF values.
The mean tumor size measured at baseline, first follow-up,
and second follow-up was 47.0±22.0 mm, 47.0±21.3 mm, and
47.0±22.1 mm, respectively.
Table 1. Adverse events after treatment
Event No. of patients (n=28)
Grade 3 or 4 All grades
Neutropenia 8 10
Nausea 4 13
Vomiting 1 2
Ileus 3 4
Neuropathy 2 17
Infection 1 1
Hyponatremia 1 1
Intestinal obstruction 2 2
Fever 3 6
Perianal infection 1 1
Abdominal infection 1 1
Operation site wound infection 1 1
AST elevation 1 1
Lumbar pain 1
Thrombus 1 1
Mental change 3 3
Proteinuria 1 2
Fatigue - 22
Weight loss - 4
Weight gain - 2
Cough - 3
Hypersensitivity - 4
Anorexia - 15
Diarrhea - 6
Constipation - 4
Hematochezia - 1
Rash - 3
Mucositis - 8
Alopecia - 1
Epistaxis - 7
Anemia - 1
Thrombocytopenia - 7
Total 34 155
AST, aspartate aminotransferase.
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3. DCE-MRI parameters and plasma CAFs as prognostic
biomarkers 
The results using Kaplan-Meier analysis indicated that PFS
time showed correlation with the dichotomized Ktrans (i.e.,
with the cut-off set at 40% reduction) variable. A  40% 
reduction in Ktrans from baseline to 3 days after bevacizumab
monotherapy showed significant association with a longer
PFS time (p=0.025). OS time did not show significant associ-
ation with the reduction in Ktrans. The changes in the other
parameters, including IAUC60 and plasma CAFs, did not
show significant correlation with PFS time (Fig. 3). 
When dichotomized at the median values for the baseline
DCE-MRI parameters, a high baseline IAUC60 (cut-off value,
10.337) showed significant association with a longer PFS time
(p=0.033), but not with a longer OS time (Fig. 3). In analysis
of the relationships between plasma CAFs and clinical out-
comes, there were no associations between baseline serum
markers and PFS or OS times. 
In multivariate analyses using the Cox regression method,
a greater reduction in Ktrans and a high baseline IAUC60 were
independent predictors for PFS time. Patients with a  40%
reduction in Ktrans from baseline to 3 days after bevacizumab
monotherapy had a 0.349 times lower hazard of disease pro-
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Fig. 2. (A-G) Changes in the values of the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma
cytokine and angiogenic factors (CAFs) parameters from baseline, first follow-up after treatment with bevacizumab alone,
and second follow-up after treatment with combined therapy. VEGF, vascular endothelial growth factor; VEGFR-2, vascular
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gression (Table 2).
The combined effects of changes in Ktrans and baseline
IAUC60 were also analyzed. The results using the Kaplan-
Meier method indicated that the patients with both a greater
change in Ktrans and a higher baseline IAUC60 experienced the
longest median PFS time (23.8 months, n=7); the patients
with both the smaller change in Ktrans and the lower baseline
IAUC60 values had the shortest median PFS times (8.1 mon-
ths, n=10, p=0.019). In multivariate analysis, compared with
the patients with the greater change in Ktrans and higher base-
line IAUC60 values, the patients with the smaller change in
Ktrans and the lower baseline IAUC60 values had a six times
greater odds of disease progression (hazard ratio [HR], 6.061;
95% CI, 1.591 to 23.09; p=0.008). The differences in OS times
were not significantly different (HR, 2.497; 95% CI, 0.643 to
9.698; p=0.186).
In multivariate analysis for treatment response at a 3-mon-
th follow-up CT, a  40% reduction in Ktrans from the baseline
to 3 days after bevacizumab monotherapy (p=0.013) and a
higher baseline IAUC60 (p=0.033) were statistically significant
independent predictors for a better response to the therapy
(Fig. 4).
No significant correlation was observed between change
in Ktrans with PFS (Pearson correlation coefficiency [r], –0.298;
p=0.124) and baseline IAUC60 with PFS (Pearson correlation
coefficiency [r], –0.270; p=0.165).
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Discussion
The OS time of 22.7 months and the PFS time of 11.2
months obtained in our study compared favorably with the
OS time of 21.3 months and the PFS time of 10.4 months 
obtained in a previous randomized controlled phase III trial
using concurrent FOLFOX-6+B regimen [1]. Although our
study was limited by the exploratory single-arm trial study
design, this result suggested that bevacizumab monotherapy
followed by concurrent FOLFOX-6+B regimen is comparable
to a concurrent FOLFOX-6+B regimen for treatment of 
colorectal cancer liver metastasis (CRCLM).
The results from this exploratory trial suggested that the
patients with  40% reduction in Ktrans by 3 days after beva-
cizumab monotherapy had a significantly longer PFS time,
suggesting that they received a clinical benefit from beva-
cizumab that those with a < 40% change in Ktrans did not 
receive. The results might imply that the prognosis for com-
bined chemotherapy using bevacizumab can be predicted by
the microvascular changes induced by bevacizumab alone.
The change was detected as early as 3 days after beva-
cizumab monotherapy, which is much earlier than the size
reductions induced by the combined therapy. Therefore, the
decision to continue with bevacizumab, or not, can be made
as early as 3 days after administration of bevacizumab
monotherapy, with minimal cost or side effects. This result
was consistent with the results of previous studies reporting
that Ktrans can be used as a prognostic biomarker that reflects
microvascular change after antiangiogenic therapy, even
when the target tumors, the drugs used, or the day that DCE-
MRI results are obtained (usually 14 days after treatment)
are different [9,11,12,19-21]. Our study results support the
hypothesis that DCE-MRI can be used as a prognostic bio-
marker for the bevacizumab therapy used for CRCLM treat-
ment.
Based on the results of our study, baseline IAUC60 values
can be used as a prognostic biomarker for the outcome of
therapy using bevacizumab. This study found that patients
with a higher than median value baseline IAUC60 had a sig-
nificantly longer PFS time, suggesting that they could receive
clinical benefit from combined therapy using bevacizumab. 
The power as a prognostic biomarker is greater when con-
sidering the change in Ktrans combined with the baseline
IAUC60 value, compared with the values considered sepa-
rately. A patient with a  40% change in Ktrans by 3 days after
bevacizumab therapy and a relatively high baseline IAUC60
should benefit from combined therapy with bevacizumab. 
This study found that all of the DCE-MRI parameters (Ktrans
and IAUC60) decreased significantly by 3 days after beva-
cizumab monotherapy, but not after combined chemother-
apy (maintaining the lower level as similar to that at 3 days
after bevacizumab monotherapy). 
These results reflected the fact that perfusion changes in
the patients with CRCLM were induced by bevacizumab
alone, but not by combined chemotherapy. When used for
the treatment of human rectal cancer, the direct effects of 
bevacizumab on tumor physiology include decreases in
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Fig. 3. Kaplan-Meier estimates for progression-free survival time for patients with low and high baseline IAUC60 values (A),
and a Ktrans reduction at the first follow-up (B).
tumor blood perfusion, blood volume, interstitial fluid pres-
sure, and microvessel density [22,23]. These effects are 
induced by a direct antipermeability effect, vasoconstriction,
a direct antiangiogenic effect inhibiting the formation of 
immature vessels, and/or apoptosis of proliferating endothe-
lial cells [8]. Since the development of antiangiogenic ther-
apy, perfusion imaging has been extensively investigated as
a method for use in validation of the biologic efficacy of the
molecular target agents on tumor tissue. DCE-MRI, one of
the imaging modalities for perfusion imaging, is advanta-
geous for the quantitative measurement of tumor microcir-
culation in vivo. This approach is noninvasive, repeatable,
without radiation hazards, and includes anatomic details of
the tumor. Because angiogenesis is a direct or indirect target
of many new anticancer drugs, DCE-MRI is an appealing
biomarker candidate for assessment of tumor angiogenic 
activity and for monitoring the effects of antiangiogenic
agents [8]. Our study results indicated that DCE-MRI can be
used a pharmacodynamic biomarker of bevacizumab ther-
apy of CRCLM. 
We also assessed the effects of bevacizumab on plasma
CAFs (IL-8, VEGF-A, vascular endothelial growth factor 
receptor 2 [VEGFR-2], and PlGF) to examine the systemic 
response. VEGF (also referred to as VEGF-A) has a crucial
role in physiological and pathological angiogenesis, and
VEGF-targeted agents have been validated as providing clin-
ical benefits in the treatment of malignant disease [22,24]. To
better understand the systemic effect of bevacizumab, which
is a VEGF-targeted agent, more information about the biol-
ogy of the VEGF ligand/receptor system is needed [24]. The
mammalian VEGF family of ligands consists of five glyco-
proteins (i.e., VEGF-A [commonly referred to as VEGF],
VEGF-B, VEGF-, VEGF-D, and PlGF). The VEGF ligands
bind to and activate three different type III receptor tyrosine
kinases (known as VEGFR-1, VEGFR-2, and VEGFR-3),
which have similar structures. Each ligand of the VEGF fam-
ily has a distinctive binding specificity for one of the three
receptors, therefore a diversity of functions can be mediated.
VEGFR-2 is the key mediator of VEGF-induced angiogenesis
[24]. Our results showed a significant decrease in circulating
VEGF-A by 3 days after bevacizumab monotherapy, but not
after combined chemotherapy. Most of the circulating VEGF-
A was likely bound to bevacizumab as early as 3 days after
bevacizumab monotherapy. This result was consistent with
our predictions and with other data from blood marker stud-
ies of bevacizumab used for the treatment of colorectal can-
cer and other cancers [7,25].
An increase in plasma PlGF levels was observed by 3 days
after bevacizumab monotherapy and a more significant 
increase by 3 days after combined chemotherapy. Inhibition
of VEGF signaling leads to a presumed compensatory 
increase in expression of other angiogenic factors, resulting
in resistance to VEGF-targeted therapy; PlGF levels increase
in plasma following blockade of VEGF signaling [24]. The
delayed response of PlGF in our study can be explained by
the consequential effect of the blockade of VEGF-A with 
Table 2. Results of multivariate analyses of the predictors of progression-free survival
Variable HR (95% CI) p-value 
Ktrans_baseline 0.716 (0.301-1.705) 0.451
Ktrans 1st follow-up_baseline 0.349 (0.133-0.912) 0.032
IAUC60_baseline 0.39 (0.159-0.957) 0.040
IAUC60 1st follow-up_baseline 1.014 (0.425-2.42) 0.975
VEGF_baseline 1.217 (0.508-2.915) 0.660
VEGF 1st follow-up_baseline 1.68 (0.224-12.589) 0.614
VEGFR-2_baseline 0.523 (0.216-1.268) 0.151
VEGFR-2 1st follow-up_baseline 4.328 (0.912-20.532) 0.065
IL-8_baseline - -
IL-8 1st follow-up_baseline 0.613 (0.205-1.833) 0.381
PlGF_baseline - -
PlGF 1st follow-up_baseline 1.034 (0.303-3.53) 0.957
The median baseline values for IL-8 and PlGF were zero, thus the baseline covariates of those parameters were excluded
from the multivariate analyses. The group with the lower baseline value, compared with the median value, was the baseline
reference group. The group with a < 40% change was the reference group for the analysis of the change in values over time.
If the change between the first follow-up and the second follow-up was not significant for a parameter, it was excluded from
the multivariate analysis. HR, hazard ratio; CI, confidence interval; VEGF, vascular endothelial growth factor; IL, interleukin;
PlGF, placental growth factor.
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bevacizumab. 
Kopetz et al. [7] reported that an elevated IL-8 level at base-
line is associated with a shorter PFS time, but our study
found no association between baseline IL-8 values and PFS
time. This result could be due to the different time points
used for plasma sampling, which were 3 days after treatment
in our study and before progression in their study (median
PFS time, 12.8 months). Circulating cytokine levels may 
reflect the responses of non-neoplastic host tissue and of neo-
plastic tumor tissue to treatment [7]. The associations 
between plasma angiogenic factors and clinical outcomes 
remain unclear, probably due to the complexities of tumor
angiogenesis, angiogenic factors, and resistance mechanisms
to the anti-angiogenic therapy [6,7,24]. 
This study had the limitation of small sample size. There-
fore, the results of our study, usefulness of Ktrans change as a
A B
C D
E
Fig. 4.  A 39-year-old male patient had rectal cancer with one hepatic metastatic lesion. (A) On the baseline image the IAUC60
value was 22.29, which was a higher baseline group value. The baseline Ktrans value was 0.187. (B) On the first follow-up
image after bevacizumab monotherapy, the patient had a 66% reduction in Ktrans (0.037). The dynamic contrast enhanced-
magnetic resonance imaging results indicated that there were no significant changes in the perfusion parameters between
the first and second follow-up (C) (0.031). Based on the large reduction in Ktrans, and the high baseline IAUC60 level, this
patient was expected to have a good response to the treatment and to have a good prognosis. Compared with the baseline
computed tomography (CT) image (D), the metastatic lesion had decreased in size by the 3-month CT follow-up (E).
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In conclusion, DCE-MRI parameters and CAFs are phar-
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our study, change in Ktrans at 3 days after bevacizumab
monotherapy was a favorable prognostic factor, but the
value of CAFs as a prognostic biomarker was not found.
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